Diabetes drug shows promise against kidney stones
NCT ID NCT07055282
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 32 times
Summary
This study tests whether empagliflozin, a medicine used for diabetes and heart conditions, can change urine chemistry to reduce the risk of forming calcium kidney stones. Researchers will give 32 adults with a history of calcium stones the drug daily for 4 weeks and measure key factors in their urine before and after. The goal is to see if the drug increases citrate and lowers stone-forming risk, which could lead to larger prevention trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY STONES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Chicago
RECRUITINGChicago, Illinois, 60637, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.